Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and accounts for the majority of lung cancer cases. According to the American Cancer Society, about 77% of all lung cancers are NSCLC.

Because NSCLC is biologically diverse, researchers need well-characterized human biospecimens to investigate disease mechanisms, molecular changes, biomarkers, and treatment responses.

At Bay Biosciences, we provide high-quality, clinical-grade NSCLC Serum Samples, plasma, peripheral blood mononuclear cells (PBMCs), and other human biospecimens for research and development purposes.

NSCLC Serum Samples

Understanding Non-Small Cell Lung Cancer

Non-small cell lung cancer develops when cells in the lungs begin growing uncontrollably and form malignant tumors.

NSCLC represents a group of lung cancers that behave similarly and share many treatment approaches.

Several histological subtypes make up NSCLC.

1. Adenocarcinoma

Adenocarcinoma is the most common subtype of NSCLC. It develops from mucus-producing glandular cells and frequently occurs in the outer regions of the lungs. Although it commonly affects smokers, it is also the most frequent lung cancer diagnosed in people who have never smoked.

2. Squamous Cell Carcinoma

Squamous cell carcinoma develops from the flat epithelial cells that line the airways. These tumors often arise near the central bronchi and are strongly associated with cigarette smoking.

3. Large Cell Carcinoma

Large cell carcinoma is a less common but highly aggressive form of NSCLC. It may develop anywhere within the lungs and tends to grow and spread more rapidly than other subtypes.

4. NSCLC Not Otherwise Specified (NSCLC-NOS)

Some tumors cannot be clearly classified under microscopic examination. These cancers are categorized as NSCLC-NOS.

Signs and Symptoms of Non-Small Cell Lung Cancer

Early-stage NSCLC often produces no obvious symptoms. As tumors enlarge or spread, patients may experience a variety of respiratory and systemic symptoms.

Common symptoms include:

When NSCLC spreads beyond the lungs, patients may also develop:

Because many of these symptoms resemble other respiratory illnesses, physicians often perform additional diagnostic testing to confirm the diagnosis.

Causes of Non-Small Cell Lung Cancer

The exact cause of NSCLC is not fully understood.

However, researchers know that the disease develops after genetic mutations accumulate within lung cells, disrupting the normal regulation of cell growth and division.

Many of these mutations occur throughout a person’s lifetime due to exposure to carcinogens and other environmental risk factors.

Common genetic alterations identified in NSCLC involve genes such as EGFR, KRAS, ALK, ROS1, BRAF, and TP53. These mutations influence tumor growth, treatment response, and prognosis.

Risk Factors for Non-Small Cell Lung Cancer

Several factors increase the likelihood of developing NSCLC.

Firstly, cigarette smoking remains the leading risk factor and accounts for the majority of lung cancer cases. Exposure to secondhand smoke also increases risk.

Secondly, prolonged exposure to radon gas, asbestos, diesel exhaust, arsenic, chromium, silica, and other occupational carcinogens contributes significantly to lung cancer development.

Thirdly, air pollution has been linked to an increased incidence of NSCLC, particularly in densely populated urban areas.

Fourthly, individuals with a personal or family history of lung cancer may inherit genetic changes that increase susceptibility to the disease.

Finally, advancing age, chronic lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and previous radiation therapy to the chest further increase risk.

Diagnosis of Non-Small Cell Lung Cancer

Early diagnosis improves treatment options and patient outcomes.

Firstly, physicians perform a physical examination and review the patient’s medical history, smoking history, and presenting symptoms.

Secondly, imaging studies such as chest X-rays, computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) help identify suspicious lung lesions and determine disease stage.

Thirdly, bronchoscopy, endobronchial ultrasound (EBUS), or needle biopsy allows physicians to obtain Lung Cancer Tissue Samples for pathological examination.

Finally, molecular testing performed on Human Tumor Tissue Samples identifies clinically important genetic alterations, including EGFR, ALK, ROS1, KRAS, and BRAF mutations, helping physicians select targeted therapies when appropriate.

Treatment of Non-Small Cell Lung Cancer

Treatment for NSCLC depends on the stage of the disease, tumor location, molecular characteristics, and the patient’s overall health.

Firstly, surgery is often the preferred treatment for patients with early-stage NSCLC.

Common procedures include wedge resection, lobectomy, pneumonectomy, or segmentectomy to remove the tumor and surrounding affected tissue.

Secondly, chemotherapy may be administered before surgery to shrink tumors or after surgery to destroy any remaining cancer cells.

Thirdly, radiation therapy uses high-energy beams to destroy cancer cells and reduce tumor growth. It may be used alone or in combination with surgery or chemotherapy.

Finally, immunotherapy has become an important treatment option for many patients with advanced NSCLC.

Researchers continue to evaluate new treatment combinations and personalized therapeutic approaches through clinical trials supported by high-quality biospecimens.

The Importance of NSCLC Serum Samples in Research

Researchers can use Non-Small Cell Lung Cancer Serum Samples to investigate:

  • Biomarker discovery and validation
  • Tumor-associated proteins
  • Immune and inflammatory markers
  • Metabolic changes
  • Molecular signatures associated with NSCLC
  • Treatment response
  • Treatment resistance
  • Disease progression
  • Early detection research
  • Development of diagnostic and prognostic assays

NSCLC Patient Serum Samples can also be studied alongside NSCLC Plasma Samples and other patient-derived biospecimens

NSCLC Serum Samples, Plasma, and Blood Samples

Different blood-derived biospecimens provide different research opportunities.

Serum samples can support studies of circulating proteins, antibodies, metabolites, and other soluble biomarkers.

Plasma samples retain clotting factors and can be used in studies involving circulating nucleic acids, extracellular vesicles, proteins, and other biomarkers.

Whole blood samples contain multiple blood cell populations and can support hematological, genomic, immunological, and molecular studies.

Researchers may also use PBMC samples to investigate immune cell populations and cellular responses associated with NSCLC.

Frequently Asked Questions

What are Non-Small Cell Lung Cancer Serum Samples?

Non-Small Cell Lung Cancer Serum Samples are serum specimens collected from individuals diagnosed with NSCLC.

What are NSCLC Serum Samples used for?

NSCLC Serum Samples can support research into circulating biomarkers, tumor-associated proteins, immune responses, metabolic changes, treatment response, and disease progression.

How are NSCLC Plasma Samples different from serum samples?

Serum is obtained after blood has clotted, while plasma is collected from blood that has been prevented from clotting. Because their compositions differ, researchers may select serum or plasma depending on the study objectives.

Can NSCLC serum samples be used with other biospecimens?

Yes. Researchers may combine serum with plasma, whole blood, PBMCs, tumor tissue, or other Human NSCLC Samples to investigate different aspects of the disease.

Supporting Your Research with Bay Biosciences

Bay Biosciences is a trusted provider of high-quality clinical research biospecimens for pharmaceutical companies, biotechnology organizations, academic institutions, and diagnostic developers.

Our comprehensive range of samples includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.